1-(benzothiazol-2-yl)-4-(1-phenylmethyl)piperazines: dopamine receptor subtype specific ligands
CA 2336150 A1 · Owner: Neurogen Corporation · Inventors: Chen, Xi
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed are compounds of formula (A) or pharmaceutically acceptable addition salts thereof wherein: R1 and R2 are the same or different and represent hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy C1-C6 alkylthio, hydroxy, amino, mono- or di(C1-C6) alkylamino cyano or trifluoromethyl; Ar represents aryl or heteroaryl, each of which is optionally substituted with R3 R4 and/or R6; R3, R4, and R6 independently represent hydrogen halogen, hydroxy, C1-C6 alkyl, C1-, C6 alkoxy perfluoro (C1-C6) alkyl, perfluoro (C1-C6) alkoxy or SO2NH2; or R3 , and R4 together with the atoms to which they are attached represent a ring having 5-7 atoms; and R5 represents hydrogen or C1-C6 alkyl which compounds …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 25, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 25, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 25, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.